THINK MULTIGENIC^®

Dr. Thomas D. Reed

Founder & CEO

Founder & CEO of BioSolution Designs (BSD). In his 20+ year tenure as Founder and Chief Science Officer of Intrexon/Precigen (Nasdaq: PGEN), Dr Reed invented foundational platforms (UltraVector & UltraPorator) and led the acquisition, optimization, and application of powerful therapeutic systems (RheoSwitch, AttSites, LEAP, and AdenoVerse). Dr Reed's efforts led to the initiation of numerous clinical programs, including Triple-Gene's INXN-4001 (Phase I), Ziopharm's Ad-RTS-hIL-12 plus Veledimex (Phase II), Fibrocell's FCX-007/D-Fi (Phase III), and the recently FDA-approved PAPZIMEOS (Aug 2025).

Shruti Abbato

Strategic Advisor

CEO, FALCON

Strategic Advisor to BioSolution Designs. Co-founder and CEO of FALCON and co-founder and COO of MULTIGENIX. Principal of Perspicere, her advisory firm for biotech strategy, transactions, and operations, since 2014. Previously CBO of SalioGen’s cell therapy division, EVP of CARMA Cell Therapies at MaxCyte, and Director of Business Development at Human Genome Sciences; began her career as a process engineer at Merck & Co. and North American Vaccine. B.S. in Chemical Engineering and B.S. in Biochemistry, University of Maryland.

Erin Collins

Chief Biologics Officer

Molecular biologist with 20 years of laboratory experience, focused on the design and optimization of biologics and their transition from the laboratory into clinical trial initiation. Experienced in managing people and projects and in process development.

William Thompson

Chief Manufacturing Officer

Leads the development, implementation, and broad adoption of manufacturing processes, systems, and technologies for next-generation biotools, platforms, and advanced therapeutics. Previously Senior Manager of GMP Cellular Therapy Manufacturing at Precigen, running UltraCAR-T clinical production campaigns, with earlier roles in quality at Seagen, CAR-T cell manufacturing for Phase I–II trials at Seattle Children’s Research Institute, and clinical and commercial autologous cellular immunotherapy manufacturing at Dendreon across the US and Europe. Holds a Master of Science.

Dr. Stephen Schauer

Chief MOD Designer

Synthetic biologist and systems modeler focused on gene regulation circuitry and construct optimization for large multigenic payloads.

Michael Linsner

Head of Comms & IR

Leads communications and investor relations for BioSolution Designs and serves as SVP of Communications & Investor Relations at IntegriGen. Previously led growth, sales, and investor liaison at OspreyBio before it joined the BioSolution Designs family of companies, and led growth for preclinical studies at Mithrl. UC Berkeley.

John Maslowski

Board of Directors

President and CEO of Forge Biologics, a gene therapy development and manufacturing company, and Chair of the Board of Directors of DEBRA of America. Former President and CEO of Castle Creek Biosciences and of Fibrocell Science, where he led development of FCX-007 (dabocemagene autoficel), an autologous gene-modified fibroblast therapy for recessive dystrophic epidermolysis bullosa. Earlier, Chief Commercial Officer at Forge and operations and quality leadership roles at Isolagen and Wyeth. Former member of the Board of Directors of the Alliance for Regenerative Medicine.

Dr. Daniel Shelly

Board of Directors

Member of the BioSolution Designs Board of Directors since 2021. Chief Business Development Officer at PolTREG and its U.S. subsidiary Immuthera, developing regulatory T-cell (Treg) and CAR-Treg therapies for autoimmune disease. Previously Vice President of Business Development and Alliances at Prescient Therapeutics, Director of Global Business Development and Strategic Partnerships at PATH, and business development leader at Albumedix, Novozymes Biopharma, and Meridian Life Science. PhD, MBA; adjunct professor, University of Cincinnati, Master’s in Drug Development program.